BRCA1 and pachyonychia congenita: (35) showed that enzalutamide, olaparib, and their combination downregulated the HR-related genes (BRCA1, RAD51AP1, RAD51C, RAD54L, and RMI2) in AR-positive PC cells, using the strategy of synergizing enzalutamide and olaparib activities in increasing PC cell apoptosis and inhibiting cell growth (35).